Article
Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.
Clinical pharmacology and therapeutics - 1 Dec 2012
Danese E, Montagnana M, Johnson J A, Rettie A E, Zambon C F, Lubitz S A, Suarez-Kurtz G, Cavallari L H, Zhao L, Huang M, Nakamura Y, Mushiroda T, Kringen M K, Borgiani P, Ciccacci C, Au N T, Langaee T, Siguret V, Loriot M A, Sagreiya H, Altman R B, Shahin M H A, Scott S A, Khalifa S I, Chowbay B, Suriapranata I M, Teichert M, Stricker B H, Taljaard M, Botton M R, Zhang J E, Pirmohamed M, Zhang X, Carlquist J F, Horne B D, Lee M T M, Pengo V, Guidi G C, Minuz P, Fava C
Abstract excerpt
A systematic review and a meta-analysis were performed to quantify the accumulated information from genetic association studies investigating the impact of the CYP4F2 rs2108622 (p.V433M) polymorphism on coumarin dose requirement. An additional aim was to explore the contribution of the CYP4F2 variant in comparison with, as well as after stratification for, the VKORC1 and CYP2C9 variants. Thirty studies involving...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.